Richard Segal

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.

Cooley advised Liminal BioSciences, a Canada-based development-stage biopharmaceutical companylisted on Nasdaq, on its all-cash cross-border sale to Structured Alpha, a fund managed by Thomvest Asset Management

Cooley advised the underwriters in Prelude Therapeutics’ $100 million follow-on offering. Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Lawyers Richard Segal, Div Gupta, Darah Protas, Sam Paullin and Katie Lapidus led the Cooley team.

Cooley advised the underwriters in Aura Biosciences’ $86.7 million follow-on offering. SVB Securities, Cowen and Evercore ISI acted as joint bookrunning managers for the offering. Aura is a clinical-stage biotechnology company that is leveraging its novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. Partners Rich Segal, Div Gupta and Daniel Goldberg led the Cooley team.